New Paradigms in Drug Discovery: How Genomic Data is Being Used to Revolutionize the Drug Discovery and Development Process: A Workshop
- When:
- March 21, 2012 (8:30 AM Eastern)
- Where:
- 20 F Street Conference Center (A & B) • 20 F Street, N.W., Washington, DC 20001 Map
- Topics:
- Biomedical and Health Research, Public Health
- Activity:
- Roundtable on Translating Genomic-Based Research for Health
- Board:
- Board on Health Sciences Policy
New drug approvals have remained reasonably steady for the past 50 years, around 20-30 a year, while at the same time the total spending on health-related R&D has tripled since 1990. There are many suspected causes for this trend including increased regulatory barriers, the rising costs of scientific inquiry, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved and in response, many companies are turning towards collaborative models of drug development, whether between industry, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process.
New technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as an individual patients’ reaction to their medications. Warfarin, Gleevec, Crizotinib, and Zelboraf are all examples of pharmaceuticals that either utilize genetic information to inform dosing or whose activity and effectiveness is determined by inherent genetic properties of the patient (i.e. a targeted therapeutic). However, even with these successes there remains skepticism over how useful genomic information will be to the larger drug development process. As the industry increasingly turns towards partnerships, it will be important to investigate how collaborations can make optimal use of genetics- and genomics-based science. In particular, how incentives can be aligned so that participants are more encouraged to contribute to these collaborations. There will also be a need to identify the success factors for the various models that are being developed, whether it is industry or academic led or a collaboration between the two.
The Roundtable on Translating Genomic-Based Research for Health will host a public workshop to investigate how genetic and genomic information is currently being and will be used in the future to improve the business of drug development. Stakeholders will be asked to present their perspectives during the workshop and may include leaders from the pharmaceutical industry, academia, and regulatory agencies.
New technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as an individual patients’ reaction to their medications. Warfarin, Gleevec, Crizotinib, and Zelboraf are all examples of pharmaceuticals that either utilize genetic information to inform dosing or whose activity and effectiveness is determined by inherent genetic properties of the patient (i.e. a targeted therapeutic). However, even with these successes there remains skepticism over how useful genomic information will be to the larger drug development process. As the industry increasingly turns towards partnerships, it will be important to investigate how collaborations can make optimal use of genetics- and genomics-based science. In particular, how incentives can be aligned so that participants are more encouraged to contribute to these collaborations. There will also be a need to identify the success factors for the various models that are being developed, whether it is industry or academic led or a collaboration between the two.
The Roundtable on Translating Genomic-Based Research for Health will host a public workshop to investigate how genetic and genomic information is currently being and will be used in the future to improve the business of drug development. Stakeholders will be asked to present their perspectives during the workshop and may include leaders from the pharmaceutical industry, academia, and regulatory agencies.
.png)
No hay comentarios:
Publicar un comentario